Pharma Strategy Blog

Commentary on Pharma & Biotech Oncology / Hematology New Product Development

  • Posts
  • About
  • KOL Interviews
  • Biotech Strategy Blog
  • Developing a predictive biomarker for PARP inhibition

    Read more
  • Update on RAF resistance in metastatic melanoma

    Read more
  • Red and Green Flags in cancer research and development

    Read more
  • Will intermittent dosing transform TKI therapy in cancer research?

    Read more
  • Making a difference in NHL and CLL: an interview with Dr Carol Gallagher

    Read more
  • Medivation announce interim results of PREVAIL in pre-chemotherapy CRPC

    Read more
  • Can Merck make an impact in pancreatic cancer?

    Read more
  • Removing the PD-1 brake enhances the effect on adoptive CAR T cells

    Read more
  • RAS mutations predict response to EGFR therapies in colorectal cancer

    Update on KRAS and NRAS mutations in colorectal cancer

    Read more
  • What’s hot at ECCO 2013 – Preview of late breakers and PI3K abstracts

    Read more
  • Overcoming drug resistance in lung cancer

    Read more
  • Making a difference in Advanced Prostate Cancer – an interview with Bertrand Tombal

    Read more
E

Developing a predictive biomarker for PARP inhibition

Is CDK12 deficiency a clinically relevant predictive biomarker of PARP1/2 inhibitor sensitivity?

View post
E

Update on RAF resistance in metastatic melanoma

The state of play in overcoming resistance to RAF inhibition in metastatic melanoma - where do we go next?

View post
E

Making a difference in NHL and CLL: an interview with Dr Carol Gallagher

Dr Carol Gallagher is the former CEO of Calistoga before it was acquired by Gilead. CAL-101, a PI3K-delta inhibitor is now known as idelalisib and in phase 3 development for CLL and indolent NHL. This is a great example of a successful R&D strategy for a targeted therapy that is making a difference to patients lives.

View post

Terms of Use
Copyright © 2006-21 Pharma Strategy Blog

error: Content is protected !!